Abstract 83P
Background
Pancreatic cancer is one of the deadliest cancers worldwide, with a 5-year survival rate of less than 10%. The dismal prognosis is primarily due to late-stage diagnosis, resulting from the absence of specific, early, and sensitive biomarkers. Macrophage inhibitory cytokine 1 (MIC-1), a member of the transforming growth factor-beta superfamily, has been proposed as a potential biomarker for the early diagnosis of pancreatic cancer. However, the existing literature reports inconsistent diagnostic performance for serum MIC-1 levels in pancreatic cancer detection. This study aims to evaluate the diagnostic accuracy of serum MIC-1 as a biomarker for pancreatic cancer.
Methods
A systematic review was performed in PubMed, Embase, Web of Science, and Scopus to identify relevant studies published up to January 2023. These studies assessed assessing usage of MIC-1 in pancreatic cancer patients, with healthy individuals serving as the comparator control group. Statistical analysis was performed using R software (version 4.0.3) with the mada package to pool sensitivity, specificity, false-positive rate estimates, diagnostic odds ratio, and positive and negative likelihood ratios; each expressed within a 95% Confidence Interval (CI).
Results
Analysis of five studies involving 2008 participants (1151 pancreatic cancer patients, 857 healthy controls) revealed a robust diagnostic performance for serum MIC-1 levels, with a high pooled sensitivity of 86.7% (95% CI, 75.4-93.3%, I2=93.9%) and specificity of 85.9% (95% CI, 66.9-94.9%, I2=94%). A false-positive rate of 14.1% (95% CI, 5.1-33.1%) was noted. Positive and negative likelihood ratios were 6.17 (95% CI, 2.37-16.05) and 0.15 (95% CI, 0.08-0.30), respectively, and a high diagnostic odds ratio of 39.92 (95% CI, 10.44-152.66) indicated strong efficacy for MIC-1 as a diagnostic biomarker.
Conclusions
Serum MIC-1 demonstrates substantial potential as an early diagnostic biomarker for pancreatic cancer due to its high sensitivity and specificity. Nevertheless, the significant heterogeneity in the studies calls for more extensive, well-designed prospective validation studies before clinical implementation.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
94P - Harnessing circulating tumor DNA in bronchoalveolar lavage fluid for precise molecular diagnosis of NSCLC
Presenter: Frank Borm
Session: Cocktail & Poster Display session
Resources:
Abstract
95P - Automatic data processing to identify EGFR mutations in pathology reports of patients with non-small cell lung cancer (NSCLC)
Presenter: Betzabel Cajiao Garcia
Session: Cocktail & Poster Display session
Resources:
Abstract
96P - Analysis of concordance between microsatellite instability by next generation sequencing (NGS-MSI) and mismatch repair deficiency by immunohistochemistry (IHC-MMR) in endometrial cancer (EC) patients
Presenter: Simona Duranti
Session: Cocktail & Poster Display session
Resources:
Abstract
97P - Prospects of liquid biopsy in determining prognosis in children with HGG and DIPG
Presenter: Olga Regentova
Session: Cocktail & Poster Display session
Resources:
Abstract
98P - Liquid biopsy in NSCLC: A promising tool to predict immunotherapy response
Presenter: Ana Fernández
Session: Cocktail & Poster Display session
Resources:
Abstract
99P - Comprehensive genomic sequencing as an ancillary diagnostic tool for pathologists
Presenter: Dan Miller
Session: Cocktail & Poster Display session
Resources:
Abstract
100P - Standard serum biomarkers to help predict a cancer diagnosis in patients with non-specific symptoms: Data from Guy´s rapid diagnostic clinic
Presenter: Maria Monroy Iglesias
Session: Cocktail & Poster Display session
Resources:
Abstract
101P - Patient-derived organoids to optimize CDK4/6 inhibitor-based treatment selection in early breast cancer
Presenter: Carla Alves
Session: Cocktail & Poster Display session
Resources:
Abstract
102P - MicroRNAs in urine and saliva as non-invasive biomarkers of minimal residual disease in pediatric acute lymphoblastic leukemia
Presenter: Alejandra Pando-Caciano
Session: Cocktail & Poster Display session
Resources:
Abstract
103P - MSI detection by NGS using tumor samples and liquid biopsy for patients with solid tumors: A single institution experience
Presenter: Alexandra Lebedeva
Session: Cocktail & Poster Display session
Resources:
Abstract